No Increase in Symptoms Toward the End of the Ocrelizumab Infusion Cycle in Patients With Multiple Sclerosis: Symptom Burden on Ocrelizumab: A Longitudinal Study (SymBOLS).

Neurol Clin Pract · 2023 · PMC10479935 · PMID 37674871

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significanceno p-value reported

There were only a few differences with borderline significance between these groups in cycle 1 or cycle 2, mostly because of the “no change group.” None of the differences were sustained in both cycles.

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.